Sixteen melanoma patients were treated using autologous monocyte-derived DC pulsed with a cocktail of gp100, MART-1, tyrosinase, MAGE-1, or MAGE-3 peptides chosen to suit the individual patient’s class I HLA molecules. Here, MAGEA3 is linked to melanoma.